Since the discovery of serum paraoxonase 1 as a serum organophosphate esterase in 1953 [1], substantial evidence has accrued linking its activity inversely with the risk of atherosclerotic cardiovascular disease (ASCVD) [2▪▪]. This evidence concerns the gene PON1 and atherosclerosis.